Hepatic steatosis detected on low‐dose computed tomography in high‐risk participants of a lung cancer screening program: a retrospective observational study

Moderate to severe hepatic steatosis was detected on low‐dose computed tomography (LDCT) in 15% of participants undergoing lung cancer screening in a retrospective observational study. Almost half of participants with hepatic steatosis (21/45) were at intermediate risk of liver fibrosis, with four participants (8.9%) at high risk based on Fibrosis‐4 scores. Based on current guidelines, these participants would be recommended to undergo further evaluation for liver disease. The clinical impact of moderate to severe hepatic steatosis incidentally detected on lung cancer screening LDCT requires further consideration and evaluation.